...Seattle Genetics Inc. (NASDAQ:SGEN) FDA grants accelerated approval to Polivy polatuzumab vedotin-piiq in combination with Treanda...

...Polivy polatuzumab vedotin-piiq from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) in combination with Treanda...

...or Treanda bendamustine from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) until Dec. 7, 2022, even though Treanda’s...
...period has expired. Bendeka is a ready-to-dilute, 10-minute infusion formulation of bendamustine, an alkylating agent. Treanda...
...request for Orphan exclusivity because Eagle had not shown that Bendeka was clinically superior to Treanda...

...PDUFA date is Aug. 19. FDA will review the antibody-drug conjugate (ADC) in combination with Treanda...
...met the primary endpoint of a greater proportion of patients achieving a complete response vs. Treanda...

...PDUFA date is Aug. 19. FDA will review the antibody-drug conjugate (ADC) in combination with Treanda...
...met the primary endpoint of a greater proportion of patients achieving a complete response vs. Treanda...

...that Venclexta plus Rituxan met the primary endpoint of improving investigator-assessed progression-free survival (PFS) versus Treanda...

...that Venclexta plus Rituxan met the primary endpoint of improving investigator-assessed progression-free survival (PFS) versus Treanda...

...that Venclexta plus Rituxan met the primary endpoint of improving investigator-assessed progression-free survival (PFS) versus Treanda...

...Genmab A/S (CSE:GEN) said Arzerra ofatumumab plus Treanda bendamustine missed the primary endpoint of improving progression-free...
...receive up to eight cycles of Treanda in combination with 12 doses of Arzerra, or Treanda...

...Genmab A/S (CSE:GEN) said Arzerra ofatumumab plus Treanda bendamustine missed the primary endpoint of improving progression-free...
...receive up to eight cycles of Treanda in combination with 12 doses of Arzerra, or Treanda...